238 related articles for article (PubMed ID: 9582606)
1. The diagnostic value of pretreatment serum LDH in patients with limited disease small-cell lung carcinoma.
Stokkel MP; Van Eck-Smit BL; Zwinderman AH; Willems LN; Pauwels EK
Int J Biol Markers; 1997; 12(4):162-7. PubMed ID: 9582606
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment serum LDH as additional staging parameter in small-cell lung carcinoma.
Stokkel MP; van Eck-Smit BL; Zwinderman AH; Willems LN; Pauwels EK
Neth J Med; 1998 Feb; 52(2):65-70. PubMed ID: 9557528
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma.
Stokkel MP; van Eck-Smit BL; Zwinderman AH; Willems LN; Pauwels EK
J Cancer Res Clin Oncol; 1998; 124(3-4):215-9. PubMed ID: 9619749
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer.
Lim SC; Park KO; Kim YC; Na KJ; Song H; Bom HS
Cancer Biother Radiopharm; 2000 Aug; 15(4):381-6. PubMed ID: 11041023
[TBL] [Abstract][Full Text] [Related]
6. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
[TBL] [Abstract][Full Text] [Related]
7. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.
Sagman U; Feld R; Evans WK; Warr D; Shepherd FA; Payne D; Pringle J; Yeoh J; DeBoer G; Malkin A
J Clin Oncol; 1991 Jun; 9(6):954-61. PubMed ID: 1851821
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.
Ray P; Quantin X; Grenìer J; Pujol JL
Cancer Detect Prev; 1998; 22(4):293-304. PubMed ID: 9674872
[TBL] [Abstract][Full Text] [Related]
11. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H
Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221
[TBL] [Abstract][Full Text] [Related]
12. Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL).
Byhardt RW; Hartz A; Libnoch JA; Hansen R; Cox JD
Int J Radiat Oncol Biol Phys; 1986 May; 12(5):771-7. PubMed ID: 3011712
[TBL] [Abstract][Full Text] [Related]
13. Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients.
Cao S; Jin S; Shen J; Cao J; Zhang H; Meng Q; Wang C; Zhang A; Zhang P; Yu Y
Oncotarget; 2017 Jan; 8(5):8657-8669. PubMed ID: 28055965
[TBL] [Abstract][Full Text] [Related]
14. The impact of dose intensity of standard chemotherapy regimens in extensive stage small cell lung cancer.
Sheehan RG; Balaban EP; Frenkel EP
Am J Clin Oncol; 1993 Jun; 16(3):250-5. PubMed ID: 8393273
[TBL] [Abstract][Full Text] [Related]
15. [Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].
Ohnoshi T; Hiraki S; Ueoka H; Kawahara S; Numata T; Nishii K; Yonei T; Yamashta H; Kiura K; Kozuka A
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1341-8. PubMed ID: 2543304
[TBL] [Abstract][Full Text] [Related]
16. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
[TBL] [Abstract][Full Text] [Related]
17. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis.
Ludbrook JJ; Truong PT; MacNeil MV; Lesperance M; Webber A; Joe H; Martins H; Lim J
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1321-30. PubMed ID: 12654444
[TBL] [Abstract][Full Text] [Related]
18. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
19. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.
Wang C; Jin S; Xu S; Cao S
Lung; 2020 Apr; 198(2):405-414. PubMed ID: 32016563
[TBL] [Abstract][Full Text] [Related]
20. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
